Abstract: Supramolecular particle compositions based on medicinal natural products (MNPs), their synthetic analogs and derivatives, and methods to prepare and use them are provided. Five classes of MNPs and their derivatives including diterpene resin acid, phytosterol, lupane-type pentacyclic triterpene, oleanane-type pentacyclic triterpene, and lanostane-type triterpene form functional nano- or micro-structures that are stable to strong acidic environment and effectively penetrate the gastrointestinal tract. Therapeutic, prophylactic, or diagnostic agents that generally have poor intestinal permeability are converted to bioavailable forms when delivered with these supramolecular particles. Among many others, small compound chemotherapeutic agents and peptide therapeutics encapsulated therein have a much greater plasma concentration following oral administration, and effectively controls and treat symptoms associated with tumors or diabetes.
Abstract: The present invention includes DNP derivatives that are useful for preventing or treating a metabolic disease or disorder in a subject in need thereof. In certain embodiments, the subject is further administered at least one additional therapeutic agent.
Abstract: In one aspect, the invention comprises compounds that bind and inhibit macrophage migration inhibitory factor. In another aspect, the invention provides methods of treating inflammatory disease, neurological disorders and cancer using the compounds of the invention.
Type:
Grant
Filed:
March 15, 2019
Date of Patent:
October 11, 2022
Assignee:
YALE UNIVERSITY
Inventors:
William L. Jorgensen, Vinay Trivedi-Parmar
Abstract: A method for forming an isoporous graded film comprising multiblock copolymers and isoporous graded films. The films have a surface layer and a bulk layer. The surface layer can have at least 1×1014 pores/m2 and a pore size distribution (dmax/dmin)) of less than 3. The bulk layer has an asymmetric structure. The films can be used in filtration applications.
Type:
Grant
Filed:
July 9, 2020
Date of Patent:
October 11, 2022
Assignees:
CORNELL UNIVERSITY, YALE UNIVERSITY
Inventors:
Ulrich B. Wiesner, Rachel M. Dorin, Joerg Werner, William A. Phillip
Abstract: The present invention provides compositions and methods of inhibiting tyrosine phosphorylation. In one aspect, a composition comprising a low-dosage tyrosine kinase inhibitor, where the low-dosage tyrosine kinase inhibitor decreases tyrosine phosphorylation, is provided. In another aspect, a method for treating cardiovascular disease or condition associated with a RASopathy having aberrant protein tyrosine phosphorylation is described. Methods for treating congenital heart disease associated with Noonan or Noonan syndrome with multiple lentigines and decreasing aberrant levels of Protein Zero-Related (PZR) tyrosyl phosphorylation are also described.
Abstract: Systems, methods, and computer-readable storage media facilitating automated testing of datasets including natural language data are disclosed. In the disclosed embodiments, rule sets may be used to condition and transform an input dataset into a format that is suitable for use with one or more artificial intelligence processes configured to extract parameters and classification information from the input dataset. The parameters and classes derived by the artificial intelligence processes may then be used to automatically generate various testing tools (e.g., scripts, test conditions, etc.) that may be executed against a test dataset, such as program code or other types of data.
Type:
Grant
Filed:
March 20, 2020
Date of Patent:
October 4, 2022
Assignees:
The University of Chicago, President and Fellows of Harvard College, Yale University
Inventors:
Dacheng Xiu, Zheng Tracy Ke, Bryan Kelly
Abstract: Provided herein are methods of determining tumoral sensitivity to hormonal (endocrine) therapy based upon an index of estrogen receptor (ER)- and progesterone receptor (PR)-related genes, referred to as the sensitivity to endocrine therapy index (SETER/PR index), and may have additional consideration for the proportion of ER gene (ESRI) RNA transcripts that contain a mutation relative to the value of the SETER/PR index. Further provided are methods of treating breast cancer patients determined to be sensitive to an endocrine therapy by the SETER/PR index.
Type:
Grant
Filed:
April 28, 2017
Date of Patent:
October 4, 2022
Assignees:
Board of Regents, The University of Texas System, Yale University
Inventors:
William Fraser Symmans, Bruno Sinn, Christos Hatzis, Chunxiao Fu, Rosanna Lau
Abstract: The present invention includes a method of using PHY906 for treating a bowel disorder including inflammatory bowel disease and irritable bowel syndrome. Particularly, the present invention provides a multiple symptoms treatment for the bowel disorder.
Type:
Grant
Filed:
October 29, 2020
Date of Patent:
September 27, 2022
Assignee:
YALE UNIVERSITY
Inventors:
Yung-Chi Cheng, Shwu-Huey Liu, Robert Tilton
Abstract: Techniques for implementing robust quantum logic gates are provided and described. In some aspects, a quantum logic gate between a plurality of cavities comprising a first cavity and a second cavity is implemented by performing a first beam splitter operation between the first cavity and the second cavity using a coupling transmon that is dispersively coupled to both the first cavity and the second cavity, and performing a controlled phase shift operation between the second cavity and an ancilla transmon that is dispersively coupled to the second cavity but not dispersively coupled to the first cavity.
Type:
Grant
Filed:
January 5, 2019
Date of Patent:
September 20, 2022
Assignee:
Yale University
Inventors:
Liang Jiang, Steven M. Girvin, Brian Lester, Yvonne Gao, Robert J. Schoelkopf, III
Abstract: Techniques for providing hardware-efficient fault-tolerant quantum operations are provided. In some aspects a cavity and an ancilla transmon are used to implement a quantum operation by encoding a logical qubit using more than two energy levels of the cavity, encoding information using more than two energy levels of the ancilla transmon, and creating an interaction between the cavity and the ancilla transmon that decouples at least one error type in the ancilla transmon from the cavity.
Type:
Grant
Filed:
January 5, 2019
Date of Patent:
September 20, 2022
Assignee:
Yale University
Inventors:
Serge Rosenblum, Philip Reinhold, Liang Jiang, Steven M. Girvin, Luigi Frunzio, Michel Devoret, Robert J. Schoelkopf, III
Abstract: The present invention includes a low dose and sustained release formulation of a mitochondrial uncoupling agent The compositions of the invention are useful for preventing or treating a disease or disorder, such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, insulin resistance and/or diabetes, in a subject in need thereof.
Type:
Grant
Filed:
July 22, 2020
Date of Patent:
September 6, 2022
Assignee:
YALE UNIVERSITY
Inventors:
Gerald I. Shulman, Rachel Jamison Perry
Abstract: Systems and methods for formal verification of programs. The systems and methods provide a new game-theoretical, strategy-based compositional semantic model for concurrency, a set of formal linking theorems for composing multithreaded and multicore concurrent layers, and a compiler that supports certified thread-safe compilation and linking. Verification of an overlay interface can include determining an intermediate strategy for a primitive operation running on an underlay interface and refining that intermediate strategy to a strategy running on the overlay interface by applying a vertical and a horizontal composition rule. The refined strategy can then be composed with compatible strategies running on the overlay interface according to a parallel composition rule. Strategies may be compatible when rely conditions imposed by each strategy satisfy guarantees provided by the other strategies. The system and method of formal verification can be applied to formal verification of smart contracts.
Type:
Grant
Filed:
November 28, 2018
Date of Patent:
August 9, 2022
Assignee:
Yale University
Inventors:
Zhong Shao, Ronghui Gu, Vilhelm Sjoberg, Jieung Kim, Jeremie Koenig
Abstract: The present invention relates in part to devices, systems, and methods for the production and characterization of engineered tissue constructs. The devices and methods generate decellularized tissue constructs that can be recellularized using donor cells for high-throughput studies of organ physiology, and/or organ pathology. The devices and methods can be used with the systems to mechanically and electrically stimulate the engineered tissue constructs under culture or physiological conditions to detect and assess the presence and degree of any organ pathologies.
Type:
Grant
Filed:
January 30, 2018
Date of Patent:
August 9, 2022
Assignee:
Yale University
Inventors:
Stuart Campbell, Jonas Schwan, Andrea Kwaczala, Thomas Ryan, Daniel Jacoby, Yibing Qyang, Lorenzo Sewanan, Ronald Ng, Jeffery Alexander Clark
Abstract: Methods and strategies for introducing genetic safeguards into microorganisms, genetically modified organisms (GMO) including the safeguards, and methods of use thereof are provided. The genetic safeguards generally impart a low escape frequency, are robust, and are modular. Safeguards with low escape frequency prevent the rise of mutants escaping defined media and limit growth in the wild. Robust safeguards retain wild-type levels of fitness while also maintaining containment in diverse growth conditions.
Type:
Grant
Filed:
September 28, 2015
Date of Patent:
August 9, 2022
Assignee:
YALE UNIVERSITY
Inventors:
Farren J. Isaacs, Ryan Gallagher, Jaymin Patel, Alexis Rovner
Abstract: Described herein are the association BV677278 (READ1) with reading disability and language impairment, as well as the synergistic interaction of DCDC2 risk haplotypes or alleles with KIAA0319 risk allele.
Abstract: Disclosed herein are methods and agents for the treatment of cancer using p53-independent apoptosis to reduce the number of p53-depleted or p53-mutated cancer cells that have amplified HER2 gene. Also disclosed herein are methods and agents for the treatment of HER2-positive cancer in individuals with Li-Fraumeni Syndrome.
Abstract: The present application provides agents that specifically inhibits the IGFBP7/CD93 signaling pathway, such as agents that specifically block the interaction between CD93 and IGFBF7, methods of using said agents and methods of identifying said agents.
Type:
Application
Filed:
March 25, 2022
Publication date:
July 28, 2022
Applicants:
YALE UNIVERSITY, The Regents of the University of Colorado, a body corporate
Inventors:
Yuwen ZHU, Lieping CHEN, Richard SCHULICK, Yi SUN
Abstract: The invention provides methods for selective targeting of live cells, which have undergone or are undergoing radiation or chemotherapy, at a site of interest with a cell-penetrating polypeptide. In one embodiment of the invention, the method comprises contacting the live cells with a cell-penetrating polypeptide comprising cell-penetrating determinants so that the cell-penetrating polypeptide binds extracellular DNA near or around the live cells so as to form a complex or association therewith such that the complex or associated polypeptide-DNA so bound bind the live cells and penetrates the live cells thereby selectively targeting live cells at a site of interest with a cell-penetrating polypeptide.
Abstract: The present invention provides compositions and methods of preparing airway cells. In one aspect, an epithelial airway cell derived from an induced pluripotent stem (iPS) cell characterized by expression of airway cell surface markers and an ability to proliferate is described. In another aspect, methods of differentiating an iPS into an epithelial airway cell is provided. Engineered lungs, methods of making such engineered lungs comprising the epithelial airway cells and treating respiratory disorders are also disclosed.